Advertisement

Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume
Decrease Volume
Seek Forward
Seek Backward
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
00:00
00:00
00:00
 

Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

2024 ASCO Annual Meeting

Advertisement

Heather Wakelee, MD, of Stanford University Medical Center, discusses phase III findings showing that the disease-free survival benefit with adjuvant atezolizumab continues to translate into a positive overall survival trend vs best supportive care in patients with stage II–IIIA non–small cell lung cancer (NSCLC). These results further support the use of adjuvant atezolizumab in PD-L1–selected populations, according to Dr. Wakelee (LBA8035).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
IMpower010, which looked at adjuvant atezolizumab for patients with completely resected early stage non-small cell lung cancer, we presented the long-term final disease-free survival as well as the second interim overall survival data, now with over 60 months of follow-up. The study had a complex hierarchical statistical design such that first group were those with PD-L1 expression stage 2 to 3A, next group, all stage 2 to 3A, then all comers, including about 12% of patients with 1B, and only if all three of those were met could we formally test overall survival. As was seen in the first interim analysis, the second interim now with the final disease-free survival in that first group with PD-L1 expression stage 2 to 3A remains robust with a hazard ratio of 0.7, translating into nearly a 30-month difference in disease-free survival. In the second group, when we look at all stage 2 to 3A, continue to see a disease-free survival benefit, which does reach statistical significance, hazard ratio of 0.85. But when we bring in that stage 1B, that drops to... Sorry, that was 0.83. ... 0.85, when we bring in that other group, no longer statistically significant. So overall survival could not be formally tested, but we do continue to see this robust disease-free survival benefit, particularly in those with PD-L1 expression. And when we look at those with the highest PD-L1 expression, greater than 50%, that disease-free survival benefit hazard ratio was 0.48. We haven't reached the median for that group of patients. And, in that group, the overall survival hazard ratio was 0.47. However, we can't formally statistically test that because of the way the trial is designed. So in conclusion, when we look at this final disease-free survival result and second interim overall survival result from IMpower010, we do continue to see robust clinical benefit for patients who have gone through surgical resection with early stage lung cancer, stage 2 to 3A, where their tumor expresses PD-L1 expression. And we do believe this continues to be a very reasonable treatment option for that subgroup of patients where there is PD-L1 expression, particularly in those with the highest PD-L1 expression of greater than 50%.

Related Videos

Prostate Cancer

Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

Anthony M. Joshua, MBBS, PhD, of Princess Margaret Cancer Centre, discusses results from the MAST study, which explored the question of whether metformin could reduce disease progression in men with low-risk prostate cancer who are undergoing active surveillance (LBA5002).

Lymphoma

Joshua D. Brody, MD, on Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Joshua D. Brody, MD, of the Icahn School of Medicine at Mount Sinai, discusses results from the EPCORE NHL-2 study, which was designed to evaluate the safety and efficacy of epcoritamab-bysp plus rituximab and lenalidomide in the first-line setting for patients with follicular lymphoma and to assess epcoritamab as maintenance therapy in this population (Abstract 7014).

Lung Cancer

Narjust Florez, MD, and David R. Spigel, MD, on Limited-Stage Small Cell Lung Cancer: Results From the ADRIATIC Study

Narjust Florez, MD, of Dana-Farber Cancer Institute, and David R. Spigel, MD, of Sarah Cannon Research Institute, discuss phase III findings showing that durvalumab as consolidation treatment after concurrent platinum-based chemoradiotherapy improved survival outcomes compared with placebo in patients with limited-stage small cell lung cancer. According to Dr. Spigel, these data support durvalumab as a new standard of care in this population (Abstract LBA5).

Prostate Cancer

Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone

Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, discusses data suggesting that adding cabazitaxel to abiraterone and prednisone improves progression-free survival in patients with metastatic castration-resistant prostate cancer who previously received chemohormonal therapy with docetaxel for hormone-sensitive disease compared with abiraterone plus prednisone alone (Abstract LBA5000).

Breast Cancer

Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection

Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay for ctDNA detection in early stage high-risk patients (LBA507).

Advertisement

Advertisement




Advertisement